Articles dans des revues avec comité de lecture (396)
  1. 25. Sabbah, M., Krayem, M., Najem, A., Sales, F., Miller, W. W., Del Rincón, S. S., Awada, A., Ghanem, G. E., & Journé, F. (2021). Dasatinib stimulates its own mechanism of resistance by activating a CRTC3/MITF/Bcl-2 pathway in melanoma with mutant or amplified c-kit. Molecular cancer research, 19(7), 1221-1233. doi:10.1158/1541-7786.MCR-20-1040
  2. 26. Aftimos, P., Rolfo, C., Rottey, S., Barthelemy, P., Borg, C., Park, K., Oh, D. Y., Kim, S. W., De Jonge, N., Hanssens, V., Zwanenpoel, K., Molthoff, C., Vugts, D., Dreier, T., Verheesen, P., van Dongen, G. A. M. S., Jacobs, J., Van Rompaey, L., Hultberg, A., Michieli, P., Pauwels, P., Fung, S., Thibault, A., De Haard, H., Leupin, N., & Awada, A. (2021). The nhance® mutation-equipped anti-met antibody argx-111 displays increased tissue penetration and anti-tumor activity in advanced cancer patients. Biomedicines, 9(6), 665. doi:10.3390/biomedicines9060665
  3. 27. Agostinetto, E., Eiger, D., Lambertini, M., Ceppi, M., Bruzzone, M., Pondé, N., Plummer, C., Awada, A., Santoro, A., Piccart-Gebhart, M., & de Azambuja, E. (2021). Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trials. European journal of cancer, 148, 76-91. doi:10.1016/j.ejca.2021.01.043
  4. 28. Olympios, N., Collet, L., Paesmans, M., Jungels, C., Kotecki, N., Awada, A., & Aftimos, P. (2021). Analyses of the Rationale and Implementation of Research Biopsies in Oncology Clinical Trials at a Tertiary Cancer Center. The oncologist. doi:10.1002/onco.13906
  5. 29. Sabbah, M., Najem, A., Krayem, M., Awada, A., Journé, F., & Ghanem, G. E. (2021). Rtk inhibitors in melanoma: From bench to bedside. Cancers (Basel), 13(7), 1685. doi:10.3390/cancers13071685
  6. 30. Franzoi, M. A., Eiger, D., Ameye, L., Pondé, N., Caparica Bitton, R., De Angelis, C., Brandao, M., Desmedt, C., Di Cosimo, S., Kotecki, N., Lambertini, M., Awada, A., Piccart-Gebhart, M., & de Azambuja, E. (2021). Clinical Implications of Body Mass Index in Metastatic Breast Cancer Patients Treated With Abemaciclib and Endocrine Therapy. Journal of the National Cancer Institute, 113(4), 462-470. doi:10.1093/jnci/djaa116
  7. 31. Demetter, P., Awada, A., Aftimos, P., Liberale, G., Jungels, C., Gomez-Galdon, M., Saiselet, M., & De Saint Aubain, N. (2021). FUS::CREM-rearranged malignant epithelioid neoplasm mimicking neuroendocrine neoplasm of unknown primary. Histopathology. doi:10.1111/his.14579
  8. 32. Cufer, T., Kosty, M., Osterlund, P., Jezdic, S., Pyle, D., Awada, A., Close, J. L. J., El Saghir, N. N., Lordick, F., Rutkowski, P., Tfayli, A., & Wildiers, H. (2021). Current landscape of ESMO/ASCO Global Curriculum adoption and medical oncology recognition: a global survey. ESMO Open. doi:10.1016/j.esmoop.2021.100219
  9. 33. Subbiah, V., Paz Ares, L., Besse, B., Moreno, V., Peters, S., Sala, M. A., López-Vilariño, J. A., Fernández, C., Kahatt, C., Alfaro, V., Siguero, M., Zeaiter, A., Zaman, K., López, R., Ponce, S., Boni, V., Arrondeau, J., Delord, J. P., Martínez, M., Wannesson, L., Anton, A., Valdivia, J., Awada, A., Kristeleit, R., Olmedo, M. E., Rubio, M. J., Sarantopoulos, J., Chawla, S., Mosquera-Martinez, J., D’ Arcangelo, M., Santoro, A., Villalobos, V. M., Sands, J., & Trigo, J. (2020). Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment. Lung cancer, 150, 90-96. doi:10.1016/j.lungcan.2020.10.003
  10. 34. Laila, B., Vinciane, L., Michael, V., Flamen, P., Awada, A., Gomez Galdon, M., & Liberale, G. (2020). Diagnosis, pathophysiology, and treatment of SIRT-induced gastroduodenal ulcers: A systematic literature review. Surgical oncology, 35, 520-526. doi:10.1016/j.suronc.2020.10.014
  11. 35. Franzoi, M. A., Vandeputte, C., Eiger, D., Caparica Bitton, R., Brandao, M., De Angelis, C., Hendlisz, A., Awada, A., Piccart-Gebhart, M., & de Azambuja, E. (2020). Computed tomography-based analyses of baseline body composition parameters and changes in breast cancer patients under treatment with CDK 4/6 inhibitors. Breast cancer research and treatment, 181, 199-209. doi:10.1007/s10549-020-05617-2
  12. 36. Krayem, M., Aftimos, P., Najem, A., van den Hooven, T., van den Berg, A., Hovestad-Bijl, L., de Wijn, R., Hilhorst, R., Ruijtenbeek, R., Sabbah, M., Kerger, J., Awada, A., Journé, F., & Ghanem, G. E. (2020). Erratum: Krayem, M., et al. Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance Short Title. Cancers (Basel), 12(10), 2981, 1-2. doi:10.3390/cancers12102981
    13. << Précédent 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36
    37     38 39 Suivant >>